101
|
Miethe C, Nix H, Martin R, Hernandez AR, Price RS. Silibinin Reduces the Impact of Obesity on Invasive Liver Cancer. Nutr Cancer 2017; 69:1272-1280. [DOI: 10.1080/01635581.2017.1367935] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
102
|
Martin CA, Martin R, Wong T, Maury P, Dallet C, Takigawa M, Frontera A, Cheniti G, Thompson N, Massouillie G, Kitamura T, Wolf M, Duchateau J, Vlachos K, Pambrun T, Denis A, Derval N, Hocini M, Haissaguerre M, Jais P, Sacher F. 37Effect of activation wavefront on electrogram characteristics during ventricular tachycardia ablation. Europace 2017. [DOI: 10.1093/europace/eux283.046] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
103
|
Frontera A, Martin R, Takigawa M, Cheniti G, Dallet C, Kitamura T, Thompson N, Wolf M, Massoullie G, Vlachos K, Denis A, Hocini M, Cochet H, Sacher F, Jaïs P, Derval N, Haïssaguerre M. 073_16987-H2 EGM Fractionation in Apparently Healthy Tissue: Time to Redefine the Voltage Threshold for Diseased Atrium? JACC Clin Electrophysiol 2017. [DOI: 10.1016/j.jacep.2017.09.034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
104
|
Palesch Y, Ramakrishnan V, Foster L, Martin R, Cassarly C, Barsan W, Moy C, Qureshi A. Antihypertensive treatment of acute cerebral hemorrhage phase iii (ATACH-II) trial: Secondary analysis of Asian and non-Asian subgroups using 24-hour blood pressure profile data. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
105
|
Martin CA, Sawhney V, Martin R, Takigawa M, Frontera A, Cheniti G, Thompson N, Massouillie G, Kitamura T, Wolf M, Duchateau J, Vlachos K, Denis A, Pambrun T, Sacher F, Hocini M, Jais P, Haissaguerre M, Ezzat V, Lowe MD, Derval N. 77USe of ultra-high density activation mapping to aid isthmus identification in atrial macro-reentrant tachycardias in complex congenital heart disease. Europace 2017. [DOI: 10.1093/europace/eux283.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
106
|
Frontera A, Takigawa M, Martin R, Thompson N, Cheniti G, Massouille G, Duchateau J, Kitamura T, Wolf M, Al-Jefairi N, Vlachos K, Yamashita S, Denis A, Hocini M, Cochet H, Sacher F, Jaïs P, Derval N, Haïssaguerre M. 073_16988-H2 Electrogram Signature of Specific Activation Patterns: Analysis of Atrial Arrhythmias at High-Density Endocardial Mapping. JACC Clin Electrophysiol 2017. [DOI: 10.1016/j.jacep.2017.09.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
107
|
Kirkham KR, Grape S, Martin R, Albrecht E. Analgesic efficacy of local infiltration analgesia vs. femoral nerve block after anterior cruciate ligament reconstruction: a systematic review and meta-analysis. Anaesthesia 2017; 72:1542-1553. [DOI: 10.1111/anae.14032] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/18/2017] [Indexed: 02/07/2023]
|
108
|
Wolf M, Sacher F, Cochet H, Kitamura T, Takigawa M, Frontera A, Cheniti G, Vlachos K, Martin R, Denis A, Pambrun T, Derval N, Hocini M, Haissaguerre M, Jais P. P1112Long-term outcome of LAVA elimination in ablation of post-myocardial infarction ventricular tachycardia. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
109
|
Chan A, De Boer R, Gan A, Willsher P, Martin R, Zissiadis Y, Miller K, Bauwens A, Hastrich D. Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study). Support Care Cancer 2017; 25:3785-3791. [PMID: 28691132 DOI: 10.1007/s00520-017-3810-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Accepted: 06/26/2017] [Indexed: 10/19/2022]
Abstract
PURPOSE Aromatase inhibitors are standard of care in women with hormone receptor-positive early breast cancer. Published evidence demonstrates that adverse effects may have an impact on drug compliance, with arthralgias being one of the most commonly reported adverse effects. METHODS Eligible patients were postmenopausal women who had experienced arthralgia following initiation of an aromatase inhibitor. Patients who experienced arthralgias following a minimum of a 3-month treatment on the aromatase inhibitor were randomized to emu oil or placebo oil. The primary endpoint was to assess for a reduction in pain as measured by a visual analogue score after 8 weeks of treatment. RESULTS Seventy-three patients comprised the intent-to-treat population, and there was no statistically significant benefit with use of EO. However, there was a statistically significant improvement in pain (visual analogue score was -1.28; p < 0.001) and Brief Pain Inventory severity score -0.88 (p < 0.001), as well as functional interference (Brief Pain Inventory interference -1.10 (p < 0.001) for the entire population following an 8-week administration of EO or placebo oil. CONCLUSIONS Arthralgias, as a result of aromatase inhibitor use, may be ameliorated by the use of topical oil massaged onto the joint. Further research into interventions for this common side effect is needed.
Collapse
|
110
|
Marzo‐Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study. Arthritis Care Res (Hoboken) 2017; 69:1020-1029. [PMID: 28235249 PMCID: PMC5518281 DOI: 10.1002/acr.23233] [Citation(s) in RCA: 72] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Revised: 02/14/2017] [Accepted: 02/21/2017] [Indexed: 12/12/2022]
Abstract
Objective Secukinumab improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks in the phase III MEASURE 2 study. Here, we report longer‐term (104 weeks) efficacy and safety results. Methods Patients with active AS were randomized to subcutaneous secukinumab 150 mg, 75 mg, or placebo at baseline; weeks 1, 2, and 3; and every 4 weeks from week 4. The primary end point was the Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response rate at week 16. Other end points included ASAS40, high‐sensitivity C‐reactive protein, ASAS5/6, Bath Ankylosing Spondylitis Disease Activity Index, Short Form 36 health survey physical component summary, ASAS partial remission, EuroQol 5‐domain measure, and Functional Assessment of Chronic Illness Therapy fatigue subscale. End points were assessed through week 104, with multiple imputation for binary variables and a mixed‐effects model repeated measures for continuous variables. Results Of 219 randomized patients, 60 of 72 (83.3%) and 57 of 73 (78.1%) patients completed 104 weeks of treatment with secukinumab 150 mg and 75 mg, respectively; ASAS20/ASAS40 response rates at week 104 were 71.5% and 47.5% with both secukinumab doses, respectively. Clinical improvements with secukinumab were sustained through week 104 across all secondary end points. Across the entire treatment period (mean secukinumab exposure 735.6 days), exposure‐adjusted incidence rates for serious infections and infestations, Crohn's disease, malignant or unspecified tumors, and major adverse cardiac events with secukinumab were 1.2, 0.7, 0.5, and 0.7 per 100 patient‐years, respectively. No cases of tuberculosis reactivation, opportunistic infections, or suicidal ideation were reported. Conclusion Secukinumab provided sustained improvement through 2 years in the signs and symptoms of AS, with a safety profile consistent with previous reports.
Collapse
|
111
|
Wolf M, Takigawa M, Derval N, Vlachos K, Kitamura T, Frontera A, Cheniti G, Martin R, Thompson N, Denis A, Pambrun T, Sacher F, Haissaguerre M, Jais P, Hocini M. P1393Pattern and timing of coronary sinus activation in complex atrial tachycardia. Europace 2017. [DOI: 10.1093/ehjci/eux158.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
112
|
Frontera A, Takigawa M, Martin R, Thompson N, Cheniti G, Kitamura T, Wolf M, Vlachos K, Massouille G, Denis A, Hocini M, Sacher F, Jais P, Haissaguerre M, Derval N. P253Can EGM fractionation occur in healthy tissue? Electrophysiological mechanism and significance during atrial tachycardia rhythm. Europace 2017. [DOI: 10.1093/ehjci/eux171.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
113
|
Wolf M, Kitamura T, Sacher F, Cochet H, Vlachos K, Cheniti G, Frontera A, Takigawa M, Martin R, Thompson N, Derval N, Denis A, Hocini M, Haissaguerre M, Jais P. 1219Comparison of procedural endpoints for ablation of post-myocardial infarction ventricular tachycardia. Europace 2017. [DOI: 10.1093/ehjci/eux154.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
114
|
Frontera A, Takigawa M, Thompson N, Martin R, Cheniti G, Kitamura T, Wolf M, Massouille G, Vlachos K, Hocini M, Denis A, Sacher F, Jais P, Haissaguerre M, Derval N. P385Relationship of voltage and EGM duration at sites of fractionation during atrial tachycardias and paced rhythms. Europace 2017. [DOI: 10.1093/ehjci/eux141.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
115
|
Wolf M, Kitamura T, Sacher F, Cochet H, Vlachos K, Cheniti G, Frontera A, Takigawa M, Martin R, Thompson N, Derval N, Denis A, Hocini M, Haissaguerre M, Jais P. 752Long-term outcome of LAVA elimination in ablation of post-myocardial infarction ventricular tachycardia. Europace 2017. [DOI: 10.1093/ehjci/eux147.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
116
|
Frontera A, Takigawa M, Kitamura T, Martin R, Vlachos K, Cheniti G, Thompson N, Massouille G, Wolf M, Hocini M, Denis A, Sacher F, Jais P, Haissaguerre M, Derval N. P386Relationship between scar and atrial tachycardia mechanisms: insight from registered magnetic resonance and ultra-high density activation mapping using the Rhythmia system. Europace 2017. [DOI: 10.1093/ehjci/eux141.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
117
|
Frontera A, Takigawa M, Martin R, Dallet C, Kitamura T, Thompson N, Cheniti G, Vlachos K, Massouille G, Denis A, Sacher F, Hocini M, Jais P, Haissaguerre M, Derval N. P383Characterization of reentrant atrial tachycardia circuits with a high density mapping system. Europace 2017. [DOI: 10.1093/ehjci/eux141.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
118
|
Frontera A, Martin R, Thompson N, Takigawa M, Kitamura T, Cheniti G, Massouille G, Vlachos K, Wolf M, Denis A, Hocini M, Sacher F, Jais P, Haissaguerre M, Derval N. P384Characterization of slow conductions areas in scar-related atrial tachycardia. Insights from high density mapping system. Europace 2017. [DOI: 10.1093/ehjci/eux141.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
119
|
Rousseau-Richard C, Richard C, Martin R. Étude cinétique de l'influence complexe, pro- ou anti-oxydante, de dérivés phénoliques sur l'oxydation induite d'un substrat polyinsaturé. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1988850175] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
120
|
Douhou S, Perrin D, Martin R. Étude cinétique et modélisation de la réaction thermique de l'isobutène vers 800 K. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1994911628] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
121
|
Rousseau C, Richard C, Martin R. Effet de synergie de la vitamine C sur les propriétés inhibitrices de la vitamine e lors de l'oxydation du linolénate de méthyle : étude cinétique et mécanisme. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1985820527] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
122
|
Perrin D, Richard C, Martin R. Étude cinétique de la réaction thermique du pentène-2 cis vers 500°C. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1988850185] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
123
|
Rousseau-Richard C, Richard C, Martin R. Étude cinétique de l'influence complexe, Pro- ou anti-oxydante, de dérivés phénoliques sur l'oxydation induite d'un substrat polyinsaturé. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1988850167] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
124
|
Delliste D, Richard C, Martin R. La réaction thermique de l'éthylène vers 500°C : modélisation au cours du temps et détermination de constantes de vitesse. ACTA ACUST UNITED AC 2017. [DOI: 10.1051/jcp/1981780655] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
|
125
|
Jerkins J, Keever-Taylor C, Heidtke S, Martin R, Esselmann J, Hari P. The use of PASV PICC lines for the infusion of thawed-washed HPC products with and without an infusion pump. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|